For example, we decided to include (i) IHC to detect ALK-positive patients, despite its use with crizotinib as an alternative to alectinib for adult patients with advanced NSCLC and (ii) FISH for trastuzumab emtansine, despite its use with trastuzumab as a neo-adjuvant therapy. This evidence concerns the gene ALK and non-small cell lung carcinoma.